Impact of the COVID-19 Pandemic on People Living With Rare Diseases and Their Families : Results of a National Survey
©Maurizio Macaluso, Marc E Rothenberg, Thomas Ferkol, Pierce Kuhnell, Henry J Kaminski, David W Kimberlin, Michael Benatar, Mirna Chehade, The Principal Investigators of the Rare Diseases Clinical Research Network – Cycle 4. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 14.02.2024..
BACKGROUND: With more than 103 million cases and 1.1 million deaths, the COVID-19 pandemic has had devastating consequences for the health system and the well-being of the entire US population. The Rare Diseases Clinical Research Network funded by the National Institutes of Health was strategically positioned to study the impact of the pandemic on the large, vulnerable population of people living with rare diseases (RDs).
OBJECTIVE: This study was designed to describe the characteristics of COVID-19 in the RD population, determine whether patient subgroups experienced increased occurrence or severity of infection and whether the pandemic changed RD symptoms and treatment, and understand the broader impact on respondents and their families.
METHODS: US residents who had an RD and were <90 years old completed a web-based survey investigating self-reported COVID-19 infection, pandemic-related changes in RD symptoms and medications, access to care, and psychological impact on self and family. We estimated the incidence of self-reported COVID-19 and compared it with that in the US population; evaluated the frequency of COVID-19 symptoms according to self-reported infection; assessed infection duration, complications and need for hospitalization; assessed the influence of the COVID-19 pandemic on RD symptoms and treatment, and whether the pandemic influenced access to care, special food and nutrition, or demand for professional psychological assistance.
RESULTS: Between May 2, 2020, and December 15, 2020, in total, 3413 individuals completed the survey. Most were female (2212/3413, 64.81%), White (3038/3413, 89.01%), and aged ≥25 years (2646/3413, 77.53%). Overall, 80.6% (2751/3413) did not acquire COVID-19, 2.08% (71/3413) acquired it, and 16.58% (566/3413) did not know. Self-reported cases represented an annual incidence rate of 2.2% (95% CI 1.7%-2.8%). COVID-19 cases were more than twice the expected (71 vs 30.3; P<.001). COVID-19 was associated with specific symptoms (loss of taste: odds ratio [OR] 38.9, 95% CI 22.4-67.6, loss of smell: OR 30.6, 95% CI 17.7-53.1) and multiple symptoms (>9 symptoms vs none: OR 82.5, 95% CI 29-234 and 5-9: OR 44.8, 95% CI 18.7-107). Median symptom duration was 16 (IQR 9-30) days. Hospitalization (7/71, 10%) and ventilator support (4/71, 6%) were uncommon. Respondents who acquired COVID-19 reported increased occurrence and severity of RD symptoms and use or dosage of select medications; those who did not acquire COVID-19 reported decreased occurrence and severity of RD symptoms and use of medications; those who did not know had an intermediate pattern. The pandemic made it difficult to access care, receive treatment, get hospitalized, and caused mood changes for respondents and their families.
CONCLUSIONS: Self-reported COVID-19 was more frequent than expected and was associated with increased prevalence and severity of RD symptoms and greater use of medications. The pandemic negatively affected access to care and caused mood changes in the respondents and family members. Continued surveillance is necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
JMIR public health and surveillance - 10(2024) vom: 14. Feb., Seite e48430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Macaluso, Maurizio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.02.2024 Date Revised 23.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2196/48430 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368441423 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368441423 | ||
| 003 | DE-627 | ||
| 005 | 20240229144423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2196/48430 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM368441423 | ||
| 035 | |a (NLM)38354030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Macaluso, Maurizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the COVID-19 Pandemic on People Living With Rare Diseases and Their Families |b Results of a National Survey |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©Maurizio Macaluso, Marc E Rothenberg, Thomas Ferkol, Pierce Kuhnell, Henry J Kaminski, David W Kimberlin, Michael Benatar, Mirna Chehade, The Principal Investigators of the Rare Diseases Clinical Research Network – Cycle 4. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 14.02.2024. | ||
| 520 | |a BACKGROUND: With more than 103 million cases and 1.1 million deaths, the COVID-19 pandemic has had devastating consequences for the health system and the well-being of the entire US population. The Rare Diseases Clinical Research Network funded by the National Institutes of Health was strategically positioned to study the impact of the pandemic on the large, vulnerable population of people living with rare diseases (RDs) | ||
| 520 | |a OBJECTIVE: This study was designed to describe the characteristics of COVID-19 in the RD population, determine whether patient subgroups experienced increased occurrence or severity of infection and whether the pandemic changed RD symptoms and treatment, and understand the broader impact on respondents and their families | ||
| 520 | |a METHODS: US residents who had an RD and were <90 years old completed a web-based survey investigating self-reported COVID-19 infection, pandemic-related changes in RD symptoms and medications, access to care, and psychological impact on self and family. We estimated the incidence of self-reported COVID-19 and compared it with that in the US population; evaluated the frequency of COVID-19 symptoms according to self-reported infection; assessed infection duration, complications and need for hospitalization; assessed the influence of the COVID-19 pandemic on RD symptoms and treatment, and whether the pandemic influenced access to care, special food and nutrition, or demand for professional psychological assistance | ||
| 520 | |a RESULTS: Between May 2, 2020, and December 15, 2020, in total, 3413 individuals completed the survey. Most were female (2212/3413, 64.81%), White (3038/3413, 89.01%), and aged ≥25 years (2646/3413, 77.53%). Overall, 80.6% (2751/3413) did not acquire COVID-19, 2.08% (71/3413) acquired it, and 16.58% (566/3413) did not know. Self-reported cases represented an annual incidence rate of 2.2% (95% CI 1.7%-2.8%). COVID-19 cases were more than twice the expected (71 vs 30.3; P<.001). COVID-19 was associated with specific symptoms (loss of taste: odds ratio [OR] 38.9, 95% CI 22.4-67.6, loss of smell: OR 30.6, 95% CI 17.7-53.1) and multiple symptoms (>9 symptoms vs none: OR 82.5, 95% CI 29-234 and 5-9: OR 44.8, 95% CI 18.7-107). Median symptom duration was 16 (IQR 9-30) days. Hospitalization (7/71, 10%) and ventilator support (4/71, 6%) were uncommon. Respondents who acquired COVID-19 reported increased occurrence and severity of RD symptoms and use or dosage of select medications; those who did not acquire COVID-19 reported decreased occurrence and severity of RD symptoms and use of medications; those who did not know had an intermediate pattern. The pandemic made it difficult to access care, receive treatment, get hospitalized, and caused mood changes for respondents and their families | ||
| 520 | |a CONCLUSIONS: Self-reported COVID-19 was more frequent than expected and was associated with increased prevalence and severity of RD symptoms and greater use of medications. The pandemic negatively affected access to care and caused mood changes in the respondents and family members. Continued surveillance is necessary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a access | |
| 650 | 4 | |a access to care | |
| 650 | 4 | |a accessibility | |
| 650 | 4 | |a changes in symptoms and use of medications | |
| 650 | 4 | |a chronic | |
| 650 | 4 | |a comorbid | |
| 650 | 4 | |a comorbidity | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a cross-sectional | |
| 650 | 4 | |a cross-sectional survey | |
| 650 | 4 | |a national | |
| 650 | 4 | |a nationwide | |
| 650 | 4 | |a psychological impact on self and family | |
| 650 | 4 | |a rare | |
| 650 | 4 | |a rare diseases | |
| 650 | 4 | |a survey | |
| 650 | 4 | |a surveys | |
| 650 | 4 | |a vulnerable | |
| 700 | 1 | |a Rothenberg, Marc E |e verfasserin |4 aut | |
| 700 | 1 | |a Ferkol, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Kuhnell, Pierce |e verfasserin |4 aut | |
| 700 | 1 | |a Kaminski, Henry J |e verfasserin |4 aut | |
| 700 | 1 | |a Kimberlin, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Benatar, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Chehade, Mirna |e verfasserin |4 aut | |
| 700 | 0 | |a Principal Investigators of the Rare Diseases Clinical Research Network – Cycle 4 |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Brendan |e investigator |4 oth | |
| 700 | 1 | |a Kim, Helen |e investigator |4 oth | |
| 700 | 1 | |a Jinnah, Hyder |e investigator |4 oth | |
| 700 | 1 | |a Sahin, Mustafa |e investigator |4 oth | |
| 700 | 1 | |a Morava-Kozicz, Eva |e investigator |4 oth | |
| 700 | 1 | |a Dugging Davis, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Vanderver, Adeline |e investigator |4 oth | |
| 700 | 1 | |a Eichler, Florian |e investigator |4 oth | |
| 700 | 1 | |a Shy, Michael |e investigator |4 oth | |
| 700 | 1 | |a Whitley, Chester |e investigator |4 oth | |
| 700 | 1 | |a Hirano, Michio |e investigator |4 oth | |
| 700 | 1 | |a Desnick, Robert |e investigator |4 oth | |
| 700 | 1 | |a Puck, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Dvorak, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Haddad, Elie |e investigator |4 oth | |
| 700 | 1 | |a Gropman, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Merkel, Peter |e investigator |4 oth | |
| 700 | 1 | |a King, Eileen |e investigator |4 oth | |
| 700 | 1 | |a Wagner, Michael |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JMIR public health and surveillance |d 2015 |g 10(2024) vom: 14. Feb., Seite e48430 |w (DE-627)NLM257939679 |x 2369-2960 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g day:14 |g month:02 |g pages:e48430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2196/48430 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |b 14 |c 02 |h e48430 | ||